CVRx, Inc. (CVRX)

NASDAQ: CVRX · Real-Time Price · USD
7.21
+0.26 (3.82%)
At close: Aug 8, 2025, 4:00 PM
7.24
+0.04 (0.49%)
After-hours: Aug 8, 2025, 4:00 PM EDT
3.82%
Market Cap189.34M
Revenue (ttm)54.65M
Net Income (ttm)-52.25M
Shares Out 26.15M
EPS (ttm)-2.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume280,251
Open6.95
Previous Close6.94
Day's Range6.94 - 7.30
52-Week Range4.30 - 18.55
Beta1.23
AnalystsBuy
Price Target14.00 (+94.31%)
Earnings DateAug 4, 2025

About CVRX

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minn... [Read more]

Sector Healthcare
IPO Date Jun 30, 2021
Employees 206
Stock Exchange NASDAQ
Ticker Symbol CVRX
Full Company Profile

Financial Performance

In 2024, CVRx, Inc.'s revenue was $51.29 million, an increase of 30.53% compared to the previous year's $39.30 million. Losses were -$59.97 million, 45.5% more than in 2023.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 94.31% from the latest price.

Price Target
$14.0
(94.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

Call Start: 16:30 January 1, 0000 5:09 PM ET CVRx, Inc. (NASDAQ:CVRX) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Jared Oasheim - Chief Financial Officer Kevin ...

4 days ago - Seeking Alpha

CVRx Reports Second Quarter 2025 Financial and Operating Results

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...

4 days ago - GlobeNewsWire

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...

10 days ago - GlobeNewsWire

CVRx Announces Positive News on Outpatient Payment for Barostim

MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...

23 days ago - GlobeNewsWire

CVRx: Sell-Off Ignores Its True Potential

CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales...

5 weeks ago - Seeking Alpha

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod...

2 months ago - GlobeNewsWire

CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript

CVRx, Inc. (NASDAQ:CVRX) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Cal...

3 months ago - Seeking Alpha

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and...

3 months ago - GlobeNewsWire

CVRx Inc: Overreaction Creates Buying Opportunity

CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with ...

4 months ago - Seeking Alpha

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday.

Other symbols: GBXRPM
4 months ago - Benzinga

CVRx Reports Preliminary First Quarter 2025 Financial Results

First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, rep...

4 months ago - GlobeNewsWire

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and le...

6 months ago - GlobeNewsWire

CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript

CVRx, Inc. (NASDAQ:CVRX) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive O...

6 months ago - Seeking Alpha

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation soluti...

6 months ago - GlobeNewsWire

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inno...

7 months ago - GlobeNewsWire

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J...

8 months ago - GlobeNewsWire

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler...

9 months ago - GlobeNewsWire

CVRx: Impressive Top-Line Growth Seems Priced In

CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a...

9 months ago - Seeking Alpha

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript

CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oas...

10 months ago - Seeking Alpha

CVRx announces new CPT® Category I codes for Barostim

MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial...

10 months ago - GlobeNewsWire

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inno...

10 months ago - GlobeNewsWire

CVRx Announces Appointment of Two New Board Members

Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members

1 year ago - GlobeNewsWire

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (...

1 year ago - GlobeNewsWire

The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...

1 year ago - Accesswire

The Schall Law Firm Is Seeking CVRx Inc Shareholders To Join Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...

1 year ago - Accesswire